[The role of growth factors in pathogenesis of hepatic lesions in patients with metabolic syndrome and chronic non-calculous cholecystitis].
Clinical examination and biochemical studies revealed hepatic functional disorders in 30 (93.75 +/- 4.28%) of 32 patients with metabolic syndrome (MS) and chronic non-calculous cholecystitis (NCC) and only in 3 (13.63 +/- 7.32%) of 22 patients with CC without MS. Most patients with CC and MS had elevated levels of fibroblast growth factor (FGF) and endothelial growth factor (EGF) suggesting activation of fibrotic processes. They were not significantly different from normal values in patients with CC without MS. Pair correlation analysis revealed the relationship between enhanced activity of the pathological process in the hepatobiliary system and increased FGF and EGS levels. It was confirmed by direct correlation between FGF. EGS levels and ALT, AST activities. Also, FGF and EGS levels were related to leptin and triglyceride levels as well as to HOMA-IR index.
N G
NG
Virstiuk
N R
NR
Seniutovich
D000328:Adult; D002764:Cholecystitis / Q000378:metabolism*; D002908:Chronic Disease; D016228:Endothelial Growth Factors / Q000378:metabolism*; D005260:Female; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism*; D008875:Middle Aged; D011379:Prognosis
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D005346:Fibroblast Growth Factors